← Eichor
Study identifier: NCT07509645 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

Condition: Ischemic Stroke  ·  Sponsor: Capital Medical University

PhasePhase 3
Planned participants348
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.

This description comes directly from the study's public registry record.

Talk to the study team

Xunming Ji  ·  01083198962  ·  jixm@ccmu.edu.cn

Chuanjie Wu  ·  01083199439  ·  wuchuanjie@ccmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (13)

Suzhou Municipal HospitalSuzhou, Anhui, ChinaRecruiting
Anyang People's HospitalAnyang, Henan, ChinaRecruiting
Nanyang Central HospitalNanyang, Henan, ChinaRecruiting
The First Affiliated Hospital of Henan Medical UniversityXinxiang, Henan, ChinaRecruiting
People's Hospital of XihuaZhoukou, Henan, ChinaRecruiting
People's Hospital of LinyiLinyi, Shandong, ChinaRecruiting
Zibo Central HospitalZibo, Shandong, ChinaRecruiting
Xianyang First People's HospitalXianyang, Shanxi, ChinaRecruiting
Yuncheng Central HospitalYuncheng, Shanxi, ChinaRecruiting
Lishui Central HospitalLishui, Zhejiang, ChinaRecruiting
Taizhou enze HospitalTaizhou, Zhejiang, ChinaRecruiting
People's Hospital of YueqingYueqing, Zhejiang, ChinaRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07509645